JP2022543702A5 - - Google Patents

Info

Publication number
JP2022543702A5
JP2022543702A5 JP2022508455A JP2022508455A JP2022543702A5 JP 2022543702 A5 JP2022543702 A5 JP 2022543702A5 JP 2022508455 A JP2022508455 A JP 2022508455A JP 2022508455 A JP2022508455 A JP 2022508455A JP 2022543702 A5 JP2022543702 A5 JP 2022543702A5
Authority
JP
Japan
Prior art keywords
ligand
seq
binding domain
receptor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543702A (ja
JP7739261B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045228 external-priority patent/WO2021030149A1/en
Publication of JP2022543702A publication Critical patent/JP2022543702A/ja
Publication of JP2022543702A5 publication Critical patent/JP2022543702A5/ja
Application granted granted Critical
Publication of JP7739261B2 publication Critical patent/JP7739261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508455A 2019-08-09 2020-08-06 ヘテロ接合性の喪失に応答する細胞表面受容体 Active JP7739261B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962885093P 2019-08-09 2019-08-09
US62/885,093 2019-08-09
US202063005670P 2020-04-06 2020-04-06
US63/005,670 2020-04-06
PCT/US2020/045228 WO2021030149A1 (en) 2019-08-09 2020-08-06 Cell-surface receptors responsive to loss of heterozygosity

Publications (3)

Publication Number Publication Date
JP2022543702A JP2022543702A (ja) 2022-10-13
JP2022543702A5 true JP2022543702A5 (cg-RX-API-DMAC7.html) 2023-08-01
JP7739261B2 JP7739261B2 (ja) 2025-09-16

Family

ID=74571174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508455A Active JP7739261B2 (ja) 2019-08-09 2020-08-06 ヘテロ接合性の喪失に応答する細胞表面受容体

Country Status (11)

Country Link
US (1) US20240173352A1 (cg-RX-API-DMAC7.html)
EP (1) EP4010377A4 (cg-RX-API-DMAC7.html)
JP (1) JP7739261B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220053587A (cg-RX-API-DMAC7.html)
CN (1) CN114585645B (cg-RX-API-DMAC7.html)
AU (1) AU2020329881A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022002465A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150071A1 (cg-RX-API-DMAC7.html)
IL (1) IL290413A (cg-RX-API-DMAC7.html)
MX (1) MX2022001711A (cg-RX-API-DMAC7.html)
WO (1) WO2021030149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2021168317A1 (en) * 2020-02-20 2021-08-26 Senti Biosciences, Inc. Inhibitory chimeric receptor architectures
US12599665B2 (en) 2020-08-13 2026-04-14 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) * 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
EP4058474B1 (en) * 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
IL304857A (en) 2021-02-16 2023-10-01 A2 Biotherapeutics Inc Preparations and methods for treating HER2 POSITIVE cancer
CA3210801A1 (en) * 2021-03-12 2022-09-15 Michael S. HWANG Engineered immune cells and uses thereof
WO2023014633A2 (en) * 2021-08-03 2023-02-09 A2 Biotherapeutics, Inc. Vector systems for delivery of two polynucleotides and methods of making and using same
AU2023213691A1 (en) * 2022-01-28 2024-09-05 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
AU2023216270A1 (en) * 2022-02-04 2024-08-15 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
US20250177445A1 (en) * 2022-03-08 2025-06-05 A2 Biotherapeutics, Inc. Engineered receptors specific to hla-e and methods of use
EP4519305A4 (en) * 2022-05-02 2026-05-06 Tscan Therapeutics Inc Compositions of multiplexed T-lymphocyte receptors, polytherapies and their uses
WO2026006575A1 (en) * 2024-06-26 2026-01-02 A2 Biotherapeutics, Inc. Immune cells with paired receptors and uses in treating autoimmunity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
US20030086929A1 (en) * 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2868121C (en) * 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CA2967222C (en) * 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
CA3034093A1 (en) * 2016-08-23 2018-03-01 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
KR102397771B1 (ko) * 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
MX2019003462A (es) 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
EP4759318A2 (en) * 2017-04-14 2026-06-17 The General Hospital Corporation Chimeric antigen receptor t cells targeting the tumor microenvironment
KR102742220B1 (ko) * 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
PL3688155T3 (pl) * 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
US11732257B2 (en) * 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
EP3724225A1 (en) * 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
BR112020022185A2 (pt) * 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
WO2021222576A1 (en) * 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same

Similar Documents

Publication Publication Date Title
Bielamowicz et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Yousefi et al. Immunotherapy of cancers comes of age
JP2021526365A5 (cg-RX-API-DMAC7.html)
Seyedin et al. Strategies for combining immunotherapy with radiation for anticancer therapy
KR102186180B1 (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
RU2015117237A (ru) Химерные антигенные рецепторы м971
Comoli et al. Development of adaptive immune effector therapies in solid tumors
Seo et al. IL21 therapy combined with PD-1 and Tim-3 blockade provides enhanced NK cell antitumor activity against MHC class I–deficient tumors
WO2016081947A4 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
Lettieri et al. Progress and opportunities for immune therapeutics in osteosarcoma
EP3666793A3 (en) Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1
Duarte et al. Gastric cancer: basic aspects
JP2023552998A5 (cg-RX-API-DMAC7.html)
JP2021500406A5 (cg-RX-API-DMAC7.html)
JP2018513687A5 (cg-RX-API-DMAC7.html)
BR112018070741A2 (pt) receptor de células t (tcr), tcr que se liga a um complexo hla-a*02, molécula de fusão a anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou projetada, composição farmacêutica, método de tratamento de um indivíduo humano em necessidade deste, formulação injetável para administração a um indivíduo humano, e método de produção de um tcr
AU2018335274A1 (en) HLA class II–restricted T cell receptors against mutated RAS
JP2020512019A5 (cg-RX-API-DMAC7.html)
JP2018520679A5 (cg-RX-API-DMAC7.html)
JP2018532407A5 (cg-RX-API-DMAC7.html)
JP2017535292A5 (cg-RX-API-DMAC7.html)
JP2022537700A5 (cg-RX-API-DMAC7.html)
Kim et al. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics
US10654934B2 (en) Use of chimeric antigen receptor modified cells to treat cancer
Rosenzweig et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis